Speedy CAR-T cells take on Hard-to-Treat myeloma in first human test
Disease control
Not yet recruiting
This early-phase study tests a new CAR-T cell therapy called UF-KURE-BCMA for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy uses a person's own immune cells, which are modified in a shorter process than standard C…
Phase: PHASE1 • Sponsor: David Wald • Aim: Disease control
Last updated May 11, 2026 20:39 UTC